Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.
Zomedica Corp (NYSE American: ZOM) delivers innovative veterinary health solutions through advanced diagnostics and therapeutic technologies for companion animals and equines. This dedicated news hub provides investors and veterinary professionals with timely updates on corporate developments directly impacting animal healthcare innovation.
Access official press releases covering product launches, financial results, and strategic partnerships that shape Zomedica's position in veterinary medicine. Our curated collection ensures transparent access to regulatory filings, technology advancements, and market expansion initiatives without promotional bias.
Key updates on Zomedica's diagnostic platforms including TRUFORMA® assays, therapeutic device innovations, and clinical validation studies. Monitor operational milestones affecting veterinary practice efficiencies and animal health outcomes through verified corporate communications.
Bookmark this page for streamlined access to Zomedica's latest developments. Combine regular visits with professional financial advice when making investment or practice management decisions related to veterinary healthcare technologies.
Zomedica Corp. has appointed Robert Cohen as Chief Executive Officer, effective January 1, 2021. Cohen, who has over 30 years of experience in the medical device and biotechnology sectors, previously served as Interim CEO and on the Board of Directors. His appointment aims to enhance shareholder value and successfully launch the TRUFORMA™ point-of-care diagnostic platform. The Board expressed confidence in Cohen's leadership during this crucial phase. The company focuses on veterinary health, providing innovative diagnostics and medical devices for dogs and cats.
Zomedica Corp. reports on the results from its Special Virtual-Only Meeting of Shareholders held on December 15, 2020.
While a majority supported the domestication proposal to Delaware, it failed to achieve the necessary 2/3 vote. Consequently, a new stock option plan will be shelved, though the current plan remains in effect. Despite this setback, Zomedica remains focused on the commercial launch of TRUFORMA™ on March 30, 2021, which utilizes advanced Bulk Acoustic Wave technology for veterinary diagnostics, protected by 70 patents.
Zomedica Corp. (NYSE American: ZOM) announced the completion of its commercial leadership team with the appointment of Debra Rock as Senior Director of Downstream Marketing & Communications. Rock's extensive background in human and animal health marketing will support the upcoming launch of the TRUFORMA diagnostics platform, set for March 30, 2021. Zomedica has approximately 70 patents related to TRUFORMA, which utilizes Bulk Acoustic Wave technology. The leadership team also includes veterans Mike Schilk and Bonnie Bragdon, who have significant experience in medical sales and veterinary affairs, respectively.
Zomedica Corp. (NYSE American: ZOM) announced its TRUFORMA™ point-of-care diagnostic platform will be commercially available on March 30, 2021. This platform, protected by 70 patents, uses Bulk Acoustic Wave (BAW) technology to enable precise diagnostics for dogs and cats. The company has developed five initial assays, including tests for thyroid and adrenal diseases, which have shown encouraging verification results against industry standards. The global companion animal diagnostics market is projected to grow from $1.7 billion in 2019 to $2.8 billion by 2024, suggesting a promising future for Zomedica.
Zomedica Corp. (NYSE American: ZOM) reported its financial results for Q3 2020, showing a net loss of $5.0 million ($0.01/share) compared to a $2.8 million loss in Q3 2019. R&D expenses surged to $2.7 million, mainly due to a milestone payment to Qorvo Biotechnologies, while total cash increased to $52.0 million from $510,586 at year-end 2019, driven by significant financing activities. Notably, net cash from financing was $28.6 million in Q3 2020, a sharp increase from previous years, partially offset by cash used in operating activities. General administrative expenses decreased by 3% and 34% for Q3 and YTD respectively.
Zomedica Corp. (NYSE American: ZOM) announced a request from Interim CEO Robert Cohen for shareholders to approve a domestication proposal at the Special Meeting on December 15, 2020. This proposal aims to reincorporate the company in Delaware, projected to save about $500,000 annually in compliance costs. Management believes this change will enhance shareholder attractiveness, particularly for institutional investors, and reflect Zomedica’s operational presence in the U.S.
Zomedica Corp. (NYSE American: ZOM), a veterinary health company, has officially changed its legal name from Zomedica Pharmaceuticals Corp., effective October 5, 2020. This decision, approved by shareholders on September 25, 2020, aims to reflect the company's focus on point-of-care diagnostic products for companion animals. Existing shareholders will not need to take any action regarding this change, although the CUSIP and ISIN numbers for shares have been updated. Interim CEO Robert Cohen expressed optimism about the company's strategic initiatives and future commercialization plans.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) held its 2020 Annual and Special Virtual-Only Meeting, where shareholders elected a new board of directors and approved several proposals, including the appointment of MNP LLP as auditors and amendments to company articles. Notably, a proposed reverse stock split was approved by majority but fell short of the two-thirds majority needed under Canadian law. The company reports approximately $50 million in cash, highlighting readiness for advancing its lead product, TRUFORMA™, while exploring listing options on major exchanges.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced that its proxy solicitor, Alliance Advisors, mailed a letter urging shareholders to vote on Proposal 3 at the upcoming Annual and Special Virtual-Only Meeting on September 25, 2020. The proposal involves a reverse stock split at a ratio of 1-for-25 to 1-for-50, aimed at increasing the share price to maintain its NYSE listing. The company warns that failing to maintain this listing could result in a shift to over-the-counter trading, negatively impacting share liquidity and value. Shareholders are encouraged to vote their shares.
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced that Robert Cohen, Interim CEO, and Stephanie Morley, President and CMO, will present at the H.C. Wainwright Virtual Global Investment Conference on September 14, 2020, at 4:00 pm ET. The presentation slides will be available on the company's website on the morning of the event. Zomedica focuses on creating innovative veterinary diagnostic products for companion animals, addressing unmet needs in veterinary care to enhance productivity and revenue for clinical veterinarians.
